Skip to main content
. 2019 May 31;9(13):3768–3779. doi: 10.7150/thno.34327

Figure 5.

Figure 5

Melatonin enhances the therapeutic effect of sorafenib in mice bearing FLT3-ITD leukemia. (A) Relative leukemia cell counts in the peripheral blood smears from leukemic mice (n=5) with different treatments. (B, C) Comparison of the spleen and liver weights from leukemic mice (n=5) with different treatments. (D) Representative peripheral blood smear and hematoxylin and eosin staining of the spleens and livers of FLT3/ITD mice (scale bar: 100 µm). (E) The survival rate of the combination group was significantly different from that of the control (P<0.001), melatonin alone (P<0.001) and sorafenib alone (P<0.001). **P<0.01 for the indicated comparison (Student's unpaired t-test). (G) The leukemic mice were weighed every 5 days for 40 days to estimate toxicity. *P<0.01 for the indicated comparison (Student's unpaired t-test).